Document Classification

Section Type: RESULTS

Text: Lasofoxifene at a dose of 0. 25 mg per day, as compared with placebo, was associated with reduced risks of vertebral fracture (16. 0 vs. 22. 4 cases per 1000 person-years ; hazard ratio, 0. 69 ; 95 % CI, 0. 57 to 0. 83) and stroke (2. 4 vs. 3. 9 cases per 1000 person-years ; hazard ratio, 0. 61 ; 95 % CI, 0. 39 to 0. 96) Both the lower and higher doses, as compared with placebo, were associated with an increase in venous thromboembolic events (3. 8 and 2. 9 cases vs. 1. 4 cases per 1000 person-years ; hazard ratios, 2. 67 [95 % CI, 1. 55 to 4. 58] and 2. 06 [95 % CI, 1. 17 to 3. 60], respectively).